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Abstract: Control of chemotherapy-induced nausea and vomiting (CINV) is a crucial factor 
in ensuring that patients undergoing cancer chemotherapy can get the full benefit of therapy. 
Current antiemetic guidelines recommend that the neurokinin-1 receptor (NK-1R) antagonist 
aprepitant should be used as part of a combination regimen with dexamethasone and a sero-
tonin receptor antagonist for the prevention of CINV in patients receiving highly emetogenic 
chemotherapy (HEC). Fosaprepitant is a water-soluble N-phosphoryl derivative of aprepitant 
that, when infused, is rapidly metabolized back to an active aprepitant. The existing literature in 
PubMed about fosaprepitant was screened and selected in order to address the emerging data from 
two randomized clinical trials evaluating the efficacy and safety of a single-dose fosaprepitant 
regimen. These phase III trials demonstrated that fosaprepitant given as a single intravenous dose 
of 150 mg was either noninferior to the conventional 3-day aprepitant or significantly superior to 
placebo for the prevention of acute and delayed CINV in patients receiving high-dose cisplatin. 
In both trials, fosaprepitant was well tolerated although more frequent infusion-site adverse 
events were observed with fosaprepitant. The new dosage regimen of fosaprepitant, therefore, 
would be an option for CINV control in patients receiving cisplatin-based chemotherapy. The 
clinical efficacy is consistent with the findings from a time-on-target, positron-emission tomo-
graphy study evaluating the NK-1R occupancy in the central nervous system (CNS) over 5 days 
after a single-dose infusion of 150 mg fosaprepitant in healthy participants. The single-dose 
regimen is capable of blocking more than 90% of the NK-1Rs in the CNS for at least 48 hours 
after infusion, which is sufficient to control delayed CINV for 2 to 5 days after HEC. The new 
dosage regimen of fosaprepitant can provide a simplified treatment option that maintains high 
protection while ensuring adherence to scheduled antiemetic medication throughout most of 
the 5-day period encompassing the major risk for CINV.
Keywords: fosaprepitant, neurokinin-1 receptor antagonist, chemotherapy-induced nausea 
and vomiting
Introduction
Cytotoxic chemotherapy remains a cornerstone of therapy for most patients with cancer 
but a high cost, in terms of adverse events and quality of life, is associated with it.1 
Many chemotherapeutic agents are associated with significant nausea and vomiting, 
which represent debilitating and feared adverse effects.2 Nausea and vomiting can 
negatively affect a patient’s quality of life as well as adherence with scheduled chemo-
therapy, leading to delay or sometimes to discontinue potentially beneficial treatment 
regimens. If poorly controlled, these adverse effects can give rise to medical complica-
tions, including poor nutrition, weight loss, dehydration, and electrolyte imbalances 
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that complicate cancer management.3 Inadequate emesis 
control may also lead to anticipatory nausea and vomiting, 
which are more difficult to control than acute or delayed 
symptoms.4 Therefore, control of chemotherapy-induced 
nausea and vomiting (CINV) is a crucial factor in ensuring 
that patients undergoing cancer chemotherapy can get the 
full benefit of therapy.
Both patient-specific and chemotherapy-related risk 
factors are known to increase the risk for developing CINV. 
Patient-specific risk factors include sex (CINV is more likely 
to occur in women), age (patients younger than 50 years 
are more likely to experience CINV), history of light or no 
alcohol consumption, prior history of CINV, emesis during 
pregnancy, history of motion sickness, and anxiety.5 The 
individual patient risk for CINV is also largely influenced by 
the intrinsic emetogenicity (based on dose, route, schedule, 
and rate of administration) of a chemotherapeutic agent.2 
The chemotherapeutic drugs have been classified into four 
emetic risk categories: high (.90% of patients will experi-
ence emesis without prophylaxis), moderate (30%–90% of 
patients will experience emesis without prophylaxis), low 
(10%–30% of patients will experience emesis without pro-
phylaxis), and minimal (,10% of patients will experience 
emesis without prophylaxis).5 Cisplatin represents the main 
example of a chemotherapeutic drug with a high emetogenic 
potential; doses greater than 50 mg/m2 cause CINV in more 
than 90% of patients if no prophylaxis is used.
CINV can be historically classified under three distinct 
categories: acute onset, delayed onset, and anticipatory.3 
Acute CINV occurs within the first 24 hours following che-
motherapy administration, whereas delayed CINV is arbi-
trarily defined as nausea and vomiting occurring after the first 
24 hours and up to 120 hours after chemotherapy is given. 
Delayed CINV can often be worse than acute symptoms 
because it is more likely to occur in a patient’s home, away 
from immediate medical assistance. Anticipatory CINV is a 
learned response that arises secondary to a history of poorly 
controlled nausea and vomiting during prior  chemotherapy.4 
A distinct clinical syndrome that may develop with adminis-
tration of chemotherapy is known as breakthrough CINV that 
occurs when, despite the best prophylaxis used, the patient 
still experiences nausea and vomiting.3
Multiple neurotransmitters have been established as 
important mediators in CINV.2 There is no single neu-
rotransmitter responsible for all forms of CINV but physi-
ologic differences exist in the pathways involved in the 
acute and delayed symptoms. The critical role of serotonin 
(5-hydroxytryptamine, 5-HT), a neurotransmitter synthesized 
in the central nervous system (CNS) and in enterochromaf-
fin cells of the gastrointestinal tract (GIT), and the 5-HT 
type-3 receptor (5-HT
3
R) in acute CINV is supported by 
preclinical models and clinical trials.6 Substance P (SP), 
a neuropeptide of the tachykinin family, via binding to the 
neurokinin-1 receptor (NK-1R) has been assumed to be a 
more relevant neurotransmitter in delayed CINV.7 SP released 
from enterochromaffin cells binds to NK-1Rs in the CNS 
and GIT, which mediates the vomiting reflex.8 In the light 
of the multiple pathways involved in the pathophysiology 
of CINV, antiemetic therapy incorporating a combination of 
several agents, which modulate neurotransmitter receptors 
in the CNS and GIT, should be administered before initial 
chemotherapy to prevent the development of both acute and 
delayed CINV.5
Corticosteroids (eg, dexamethasone) and 5-HT
3
R 
antagonists have been the mainstay of antiemetic prophylaxis 
in patients receiving highly and moderately emetogenic 
chemotherapy (HEC and MEC). The 5-HT
3
R antagonists 
combined with dexamethasone dramatically improved the 
control of acute CINV caused by HEC regimens.9,10 A more 
recent development has been the NK-1R antagonist class, 
which targets the SP activity at NK-1Rs in the CNS and is 
more effective against delayed CINV. Well-designed phase 
III trials demonstrated that the addition of oral aprepitant to 
ondansetron plus dexamethasone increases the proportion 
of patients achieving complete response (CR; defined as 
no vomiting and no rescue antiemetics) by 9%–21% dur-
ing the first 120 hours following chemotherapy containing 
cisplatin or the combination of an anthracycline plus cyclo-
phosphamide (AC).11–13 In 2003, the potent and selective SP 
antagonist, aprepitant became the first and still remains the 
only NK-1R antagonist clinically available for the control 
of acute and delayed CINV in cancer patients.14–16 The cur-
rently approved 3-day dosing regimen for orally administered 
aprepitant is 125 mg before chemotherapy initiation followed 
by 80 mg on days 2 and 3. It has been demonstrated that 
the maximal antiemetic efficacy of aprepitant is associated 
with greater than 90% occupancy of NK-1Rs in the human 
CNS and this high level of occupancy would be achieved 
with the conventional 3-day oral regimen.17 The approval of 
fosa prepitant dimeglumine (hereafter referred to as fosa-
prepitant), an intravenous prodrug of aprepitant, increased 
the delivery options available to oncologists and patients 
and provided maximum clinical dosing flexibility.
The existing literature in PubMed about fosaprepitant 
in the prevention of acute and delayed CINV was screened 
and selected in order to address the emerging data from 
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two randomized clinical trials evaluating the efficacy and 
safety of a single-dose fosaprepitant regimen in patients 
receiving HEC.
Fosaprepitant as an alternative  
on day 1 of a 3-day oral aprepitant:  
an overview
Fosaprepitant (Emend® for injection, Ivemend®, Merck & 
Co., Inc, Whitehouse Station, NJ, USA) is a water-soluble 
N-phosphoryl derivative of aprepitant,14 which, when infused, 
is rapidly metabolized back to active aprepitant by ubiquitous 
phosphatases.18 Therefore, the antiemetic efficacy of the intra-
venous prodrug is attributed entirely to aprepitant. Fosaprepitant 
also follows the metabolic pathway of aprepitant, which is 
metabolized in the liver by cytochrome P450 (CYP) enzymes, 
primarily by CYP3A4.19 Since aprepitant is a weak-to-moderate 
(dose-dependent) inhibitor and inducer of CYP3A4, caution 
should be taken when administering fosaprepitant/aprepitant 
with drugs such as corticosteroids that are primarily metabo-
lized by this enzyme because it may result in increases in the 
area under the plasma concentration-time curve (AUC) of these 
drugs and of aprepitant itself.20 The safety of fosaprepitant was 
assessed in several phase I clinical trials with approximately 
700 participants/patients.21 In most of these studies, single 
doses ranging from 0.2 to 200 mg were administered, and a 
concentration of 1 mg/mL infused over 15 to 30 minutes was 
associated with acceptable venous tolerability.
In the initial development of aprepitant, two phase II  trials 
were conducted with the use of fosaprepitant in patients receiv-
ing their first dose of cisplatin.22,23 Overall, these early studies 
involving small numbers of patients receiving no standardized 
dosages and combinations of antiemetic agents15,16 suggested 
that fosaprepitant could be investigated as an alternative 
intravenous formulation to oral aprepitant. In 2007, a random-
ized, open-label, crossover study of 106 healthy participants 
showed that the 115 mg fosaprepitant dose administered over 
15 minutes provides an AUC equivalent to that of the 125 mg 
oral aprepitant dose on day 1.21 In this study fosaprepitant was 
well tolerated at doses up to 150 mg. Another randomized, 
double-blind, crossover study showed no meaningful increases 
in QTc intervals in healthy participants receiving a 200 mg 
dose of fosaprepitant.24 A recent systematic review with a 
meta-analysis evaluating the overall impact of NK-1R antago-
nists on CINV prevention showed that, among patients given 
aprepitant, 1459 of 2268 (64.3%) achieved CR versus 977 of 
1972 (49.5%) in the control group during the first 120 hours 
following chemotherapy initiation (odds ratio [OR] 0.53; 95% 
confidence interval [CI]: 0.45 to 0.61; P , 0.00001).25
In 2008, fosaprepitant was approved as a substitution dose 
(115 mg) for the 125 mg oral capsule of aprepitant on day 1 
of a 3-day regimen for the prevention of acute and delayed 
CINV caused by HEC and MEC.
Focus on the single-dose  
fosaprepitant regimen  
for the prevention of CINV
Rationale
During the development of aprepitant, a positron-emission 
tomography (PET) tracer was developed to assess the NK-1R 
occupancy by therapeutic doses of aprepitant in the living 
human CNS.14 The findings were important to select the 
dosing regimen capable of ensuring the lowest aprepitant 
exposure that produced more than 90% of NK-1R occu-
pancy in the CNS.17 However, daily doses of aprepitant 
higher than those currently used (up to 375 mg) were well 
tolerated,26 and a pharmacokinetic study suggested that a 
single 300 mg dose of aprepitant was capable of maintaining 
circulating levels over an extended period of time similar to 
those of the conventional 3-day regimen.27 A preliminary 
investigation of a single-day three-drug regimen consisting 
of the second-generation 5-HT
3
R antagonist palonosetron 
(0.25 mg intravenously) plus dexamethasone (20 mg orally) 
and aprepitant (285 mg orally) demonstrated a high degree 
of efficacy against both acute and delayed CINV caused by 
MEC.28 In addition, a pilot randomized trial of patients who 
were receiving palonosetron, dexamethasone, and aprepi-
tant for control of CINV caused by HEC, suggested similar 
efficacy of a 1-day (125 mg orally) and the standard 3-day 
regimen of aprepitant.29 Therefore, phase III trials were 
designed to evaluate the efficacy, safety, and tolerability of a 
single 150 mg intravenous dose of fosaprepitant in a regimen 
not requiring subsequent administration of oral aprepitant 
on days 2 and 3 after chemotherapy initiation. The dose of 
fosaprepitant was selected because it is within the range of 
previously evaluated doses,21 and the predicted NK-1R occu-
pancy in the CNS with this dose would exceed 90%.17
Safety
The safety and tolerability of fosaprepitant have been reported 
to be similar to those of aprepitant because it is rapidly con-
verted to aprepitant following infusion, without significant 
tissue distribution of the prodrug.30 A recent meta-analysis 
of 17 clinical trials (n = 8740) assessing several different 
NK-1R antagonists analyzed the occurrence of adverse events 
in the first cycle of chemotherapy.25 In this large popula-
tion (44.5% of the patients received aprepitant), any grade 
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asthenia (OR = 1.23, 95% CI: 1.05 to 1.45; P = 0.01), any 
grade hiccups (OR = 1.30, 95% CI: 1.03 to 1.64; P = 0.03), 
and severe infection, as defined by the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
CTCAEv3.0, (OR = 3.10, 95% CI: 1.69 to 5.67; P , 0.001) 
occurred more frequently among patients in the NK-1R 
antagonist group. Any grade constipation (OR = 0.79, 95% 
CI: 0.69 to 0.90; P , 0.001) was more common in the control 
group, whereas the use of NK-1R antagonists was not associ-
ated with an increase in the risk of diarrhea (OR = 1.06, 95% 
CI: 0.87 to 1.30; P = 0.56). The association between NK-1R 
antagonists and severe infection needs a few comments. This 
analysis was derived from only three trials of aprepitant, 
but supported the finding of a significant increase (from 2% 
to 6%) in the risk of severe infection among patients who 
received the NK-1R antagonist.12,26,31 Although aprepitant 
may increase the plasma concentration of dexamethasone 
due to the CYP3A4 inhibitory effect of the drug,20 there were 
similar frequencies of severe infection among patients who 
did not receive a decreased dexamethasone dose26 and those 
who did.12,31 Aprepitant can also increase the exposure to 
chemotherapy agents metabolized by CYP3A4, but the rate 
of febrile neutropenia or any other hematological toxicity 
was not more frequent among patients who received NK-1R 
antagonists compared with those in the control group.25
The incidence of the most regularly encountered adverse 
events, except for infusion-site reactions, in two recent 
phase III trials evaluating the single-dose fosaprepitant 
 regimen (150 mg on day 1) are listed in Table 1. In the 
Grunberg study, the adverse event profile for the fosa-
prepitant group was consistent with that observed in patients 
receiving the conventional 3-day aprepitant.32 There was 
a higher incidence of asthenia and anorexia in patients 
treated with aprepitant compared with patients treated with 
 fosaprepitant. No difference in the overall incidence of infec-
tions was observed between treatment groups, but urinary 
tract infections were more common with fosaprepitant. In 
the Saito study, the overall incidence of drug-related adverse 
events did not differ  significantly between the fosaprepitant 
group and the control group including placebo (26% vs 
28%; P = 0.80).33 There was no significant difference in the 
incidence of serious drug-related adverse events (0.6% vs 
0.6%; P = 0.98) between treatment groups. It also should 
be noted that 44% of the patients in the fosaprepitant group 
and 37% in the control group received chemotherapy 
agents metabolized by CYP3A4. However, the incidence 
of chemotherapy-related hematological toxicity including 
febrile neutropenia (fosaprepitant, 2%; placebo, 3.5%), 
neutropenia (fosaprepitant, 51%; placebo, 54%), and throm-
bocytopenia (fosaprepitant, 33%; placebo, 37%) was similar 
between treatment groups.33
In both studies, the patients were also assessed for 
the occurrence of infusion-site reactions (Table 2). In the 
 Grunberg study, there were significantly more cases of 
infusion-associated thrombophlebitis with fosaprepitant 
than with aprepitant (0.8% vs 0.1%; P = 0.005).32 Of the 
nine cases of thrombophlebitis reported in patients receiving 
fosaprepitant, only three were considered related to the study 
drug according to investigator assessment. In the Saito study, 
the overall incidence of infusion-related adverse events was 
significantly higher in the fosaprepitant group than in the 
control group (24% vs 12%; P = 0.006).33 Although severe 
events were not observed, a slight increase in the incidence 
of moderate-grade adverse events was noted for patients in 
the fosaprepitant group compared with patients in the control 
group (3% vs 2%; P = 0.32).
Efficacy
Two multicenter, randomized, double-blind, phase III trials 
have recently investigated the antiemetic efficacy of a single-
dose fosaprepitant regimen in patients scheduled to receive 
high-dose cisplatin ($70 mg/m2) (Table 3). The Grunberg 
study including 2,322 patients compared fosaprepitant 
(150 mg on day 1) to the conventional 3-day aprepitant, both 
in combination with ondansetron (32 mg intravenously on 
day 1) plus dexamethasone.32 Concomitant dexamethasone 
Table 1 Adverse events in phase III clinical trials with single-dose fosaprepitant regimen in patients receiving cisplatin
Study (year) N Antiemetics Incidence of adverse events, any gradea (%)
Total Anorexia Constipation Diarrhea Vomiting Asthenia Nausea Hiccups
Grunberg et al 
(2011)32
2,322 D + O + FOS 
D + O + APR
NR 
NR
7 
9
11 
10
8 
9
7 
6
9 
12
6 
7
6 
6
Saito et al 
(2012)33
347 D + G + FOS 
D + G + PLA
26 
28
52b 
48b
40 
33
NR 
NR
NR 
NR
29c 
27c
44 
44
32 
35
Notes: aCategorized by using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0; bpercentage of patients complaining of reduced 
appetite; cpercentage of patients complaining of malaise.
Abbreviations: D, dexamethasone; O, ondansetron; FOS, fosaprepitant; APR, aprepitant; G, granisetron; PLA, placebo; NR, not reported.
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was administered as a 12 mg oral dose on day 1 followed by 
either 8 mg orally on day 2 and 8 mg twice daily on days 3 
and 4 (for fosaprepitant group) or 8 mg orally on days 2–4 
(for aprepitant group). The primary end-point was CR during 
the overall phase (days 1–5 post-chemotherapy). The study 
was designed as a noninferiority study with an expected CR 
rate of 67.7% in each treatment group and a noninferiority 
margin of -7 percentage points. In the fosaprepitant group, 
71.9% of the patients achieved CR compared with 72.3% 
in the aprepitant group, a between-treatment difference 
of -0.4 percentage points (95% CI: -4.1 to 3.3).32 As the 
lower boundary of the 95% CI for the difference in CR rates 
between treatment groups was greater than the prespecified 
value of -7 percentage points, the study hypothesis that 
single-dose fosaprepitant was noninferior to aprepitant was 
supported in the primary analysis. The fosaprepitant regimen 
was noninferior to the aprepitant regimen also with respect 
to the secondary end-point of CR during the delayed phase 
(days 2–5 postchemotherapy). For the secondary end-point 
of no vomiting during the overall phase, similar rates of 
free-vomiting patients were observed in the two treatment 
groups (73% vs 75% in the fosaprepitant and aprepitant 
groups, respectively). Similar rates of nausea-free patients 
were observed between treatment groups in the overall phase 
(53% vs 51% in the fosaprepitant and aprepitant groups, 
respectively). No rescue medication was used during the 
overall phase by a similar proportion of patients (90%) in 
each treatment group.
The Saito study including 347 patients compared fosa-
prepitant (150 mg on day 1) to placebo, both treatment groups 
including also granisetron (0.04 mg/kg intravenously on day 1) 
and dexamethasone.33 Patients in the fosaprepitant group 
received a 10 mg intravenous dose of dexamethasone on day 
1 followed by a 4 mg intravenous dose on day 2 and 8 mg 
on day 3, whereas patients in the control group received a 
20 mg intravenous dose of dexamethasone on day 1  followed 
by a 8 mg intravenous dose on days 2 and 3. The study was 
designed as a superiority trial, and the primary end-point was 
CR during the overall phase (days 1–5 post-chemotherapy). 
The proportion of patients achieving CR in the overall phase 
was significantly higher in the fosaprepitant group than in 
the control group (64% vs 47%; P = 0.001).33 In the acute 
and delayed phases, the rates of patients achieving CR were 
also significantly higher in the fosaprepitant group than in 
control group. The fosaprepitant regimen was significantly 
superior to the control regimen with respect to the secondary 
end-points of complete protection (defined as no emesis, no 
rescue antiemetics, and nausea of no more than mild severity) T
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and no emesis during all the study periods. In terms of nausea 
control, no significant differences were observed between 
treatment groups during all the study periods.
Both phase III trials demonstrated that a three-drug anti-
emetic prophylaxis containing the single-dose fosaprepitant 
regimen is effective and well tolerated in controlling acute 
and delayed CINV in patients receiving high-dose cisplatin. 
The clinical efficacy is consistent with the recent findings 
from a time-on-target PET study that compared the NK-1R 
occupancy in the CNS over 5 days after a single-dose infu-
sion of 150 mg fosaprepitant to that achieved after single-
dose oral administration of 165 mg aprepitant in 16 healthy 
participants.34 The rates of NK-1R occupancy in the CNS 
after fosaprepitant at the time to peak concentration (T
max
; 
approximately 30 minutes), 24, 48, and 120 hours after the 
dose were 100%, 100%, $97%, and 41%–75%, respectively. 
After aprepitant, the rates of NK-1R occupancy at these time 
points (T
max
; approximately 4 hours) were $99%, $99%, 
$97%, and 37%–76%, respectively. Therefore, the 150 mg 
single-dose of fosaprepitant on day 1 is capable of blocking 
more than 90% of the NK-1Rs in the CNS for at least 48 hours 
after infusion, which is sufficient to control delayed CINV 
for 2 to 5 days after HEC.
Patient acceptability
Patients with advanced cancer have to deal with deteriorating 
physical health, and symptom management is of paramount 
importance in ensuring optimal quality of life. Therefore, 
advances in the prevention of CINV represent one of the 
major achievements in supportive care.15,16 Since most of the 
cytotoxic therapies are still given by an intravenous route, 
it is evident that there may be an indication for intravenous 
antiemetics not only in patients with severe mucositis, dif-
ficulty in swallowing or any gastrointestinal disturbances. 
Recent clinical research on CINV has demonstrated that a 
single injection of 150 mg fosaprepitant is an option that 
is not  associated with significant reduction in antiemetic 
control during the 5-day period following cisplatin-based 
chemotherapy.32 More importantly, a similar proportion of 
patients receiving either fosaprepitant or the conventional 
3-day aprepitant regimen required antiemetic rescue medi-
cation, indicating that fosaprepitant was indeed noninferior 
during the overall risk period. The efficacy of the new dosage 
regimen of fosaprepitant was also demonstrated in a placebo-
controlled trial in patients receiving cisplatin. The opportu-
nity of replacing aprepitant with a more convenient dosing 
regimen is expected to improve adherence and simplify anti-
emetic medication schedules for patients. To our knowledge, 
there are no data available to date regarding acceptability 
of fosaprepitant in patients receiving chemotherapy. This 
is probably because the development of the intravenous 
prodrug has been hampered by the initial preference of the 
manufacturer for oral aprepitant. However, the important 
issue of patient’s acceptability needs some considerations 
taking into account new perspectives for fosaprepitant in 
CINV management and research.
Recent findings indicate that, despite achievements 
in research on new antiemetics, CINV still remains an 
important clinical problem.35,36 Since preventing rather than 
treating CINV should be the primary goal, it is extremely 
important that each patient undergoing emetogenic chemo-
therapy receives optimal prophylaxis starting from cycle 1 of 
therapy.15,16 However, some physicians may be not aggressive 
enough in prescribing prophylaxis,37 while some patients 
may be nonadherent in taking their medication as prescribed 
and, therefore, are not able to fully benefit from antiemetic 
prophylaxis.38 Accurate communication between physicians 
and patients is particularly important to improve the control 
of CINV but physicians and patients may have different 
expectations regarding CINV  management. Oncologists 
and oncology nurses may underestimate the incidence of 
delayed CINV,39 while patients undergoing chemotherapy 
Table 3 Complete response rates from phase III clinical trials with single-dose fosaprepitant regimen in patients receiving cisplatin
Author  
(year)
Study design N Antiemetics 
(administration schedule)
Study period CR (%)
Fosaprepitant Comparator
Grunberg  
et al (2011)32
Noninferiority 2,322 D (4 days) + O (1 day) + FOS (1 day) 
D (4 days) + O (1 day) + APR (3 days)
Day 1 
Days 2–5 
Days 1–5
89 
74 
72a
88 
74 
72
Saito  
et al (2012)33
Superiority 347 D (3 days) + G (1 day) + FOS (1 day) 
D (3 days) + G (1 day) + PLA (1 day)
Day 1 
Days 2–5 
Days 1–5
94b 
65b 
64b,c
81 
49 
47
Notes: aNoninferiority hypothesis was proven as the lower boundary of the 95% CI for between-group difference was greater than the preset threshold (-7%); bP , 0.005; 
cprimary end-point.
Abbreviations: CI, confidence interval; CR, complete response (defined as no vomiting, and no rescue antiemetics); D, dexamethasone; O, ondansetron; FOS, fosaprepitant; 
APR, aprepitant; G, granisetron; PLA, placebo.
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are more likely than physicians to minimize their nausea 
and vomiting relative to other problems.40 Furthermore, 
among the factors frequently associated with nonadherence 
complexity of the dosing regimen can adversely influence 
adherence to recommended oral therapies.38 In this scenario, 
the single-dose fosaprepitant regimen can help to minimize 
medication administration that patients must remember at 
home and provide the potential to decrease the number of 
patients receiving a suboptimal antiemetic prophylaxis.
Evidence-based recommendations for optimal manage-
ment of CINV have been devised by international organiza-
tions including the American Society of Clinical Oncology 
(ASCO), European Society for Medical Oncology (ESMO), 
Multinational Association for Supportive Care in Cancer 
(MASCC), and National Comprehensive Cancer Network 
(NCCN).15,16,41 All updated guidelines are almost identical and 
set out a multi-drug approach to CINV control for patients 
receiving HEC and MEC regimens. One exception is the 
combination of AC that is frequently used to treat a large 
group of cancer patients, most typically women with breast 
cancer. Women receiving the AC combination represent a 
situation with a particularly high emetic potential.16 In the 
light of this, the ASCO and NCCN guidelines have recently 
reclassified the AC combination as HEC, while the MASCC/
ESMO guidelines still label this regimen as MEC.15,16,41 
However, the MASCC/ESMO guidelines separate the AC 
combination from other MEC. In spite of this difference, 
all guidelines are consistent in recommending the use of 
three-drug regimens including a NK-1R antagonist (ie, 
3-day aprepitant or single-dose fosaprepitant regimen) for 
prevention of CINV caused by HEC even if the MASCC/
ESMO guidelines (that are updated only every 2 years) still 
recommend the use of fosaprepitant only as an alternative 
on day 1 of a 3-day aprepitant regimen (Table 4).
Antiemetic three-drug regimens may be inconvenient and 
cumbersome because continued prophylaxis with oral agents 
for at least 3 days is commonly recommended. It also should 
be pointed out that, in clinical practice, the oncologists are 
more likely to pay close attention to treatment guidelines for 
a cancer than supportive care guidelines devised to enhance 
the tolerability of the anticancer treatment being given.42 
A recent, prospective, observational European study showed 
that the use of guideline-consistent CINV prophylaxis was 
only 55% and 46% during acute and delayed time periods, 
respectively, and 29% for the overall study period after 
cycle 1 of HEC or MEC.43 In addition, a low rate of adherence 
to outpatient antiemetic delayed therapy, especially for dex-
amethasone, has been recently reported among breast cancer 
patients receiving anthracycline-based  chemotherapy.44 It has 
been suggested that one promising strategy to improve both 
clinical implementation of guidelines and patient’s adherence 
is to simplify the antiemetic regimen and thereby administer 
all antiemetic agents as single doses before chemotherapy 
initiation without scheduled medication administration at 
home.28 In the light of this, the single-dose fosaprepitant 
regimen not only can allow shorter, more convenient dos-
ing schedule for the NK-1R antagonist but also retain the 
potential of achieving dexamethasone exposure to continue 
for multiple days even after a single corticosteroid dose. 
It has been shown that aprepitant-induced inhibition of 
dexamethasone metabolism can cause an extended expo-
sure to dexamethasone that can provide protection for the 
entire period of major risk for acute and delayed CINV.28 
 Furthermore, the feasibility of a dexamethasone-sparing 
strategy could be maximized by the use of single-dose 
palonosetron, a long-acting 5-HT
3
R antagonist with an half-
life of approximately 40 hours, which can obtain an extended 
5-HT antagonist effect.45 Recent phase III trials demonstrated 
Table 4 Recommended antiemetic regimens for HEC and AC-containing regimens based on the major international guidelines
Guidelines Emetic risk Recommended antiemetic therapy
Day 1 Beyond day 1
ASCO15 Higha 5-HT3RA + NK-1RAb + Dexamethasone Dexamethasone + Aprepitantd
MASCC/ESMO16 High 5-HT3RA + NK-1RAc + Dexamethasone Dexamethasone + Aprepitant
Moderate (AC combinations) 5-HT3RA
e + NK-1RAc + Dexamethasone Aprepitant
NCCN41 Higha 5-HT3RA (palonosetron preferred) +  
NK-1RAb + Dexamethasone ± lorazepam ±  
H2 blocker or proton pump inhibitor
Dexamethasone + Aprepitantd ±  
lorazepam ± H2 blocker or proton 
pump inhibitor
Notes: aBoth ASCO and NCCN guidelines have reclassified the AC combination as highly emetogenic chemotherapy; bintravenous fosaprepitant 150 mg or oral aprepitant 
125 mg; cintravenous fosaprepitant 115 mg or oral aprepitant 125 mg; dwhen aprepitant is used on day 1; eif an NK-1RA is not available for the AC combination, palonosetron 
plus dexamethasone is the preferred 5-HT3RA.
Abbreviations: HEC, highly emetogenic chemotherapy; AC, anthracycline and cyclophosphamide; 5-HT3RA, 5-HT3 receptor antagonist; NK-1RA, NK-1 receptor 
antagonist; ASCO, American Society of Clinical Oncology; MASCC/ESMO, Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology; 
NCCN, National Comprehensive Cancer Network.
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that  palonosetron plus single-dose dexamethasone adminis-
tered either before a broad range of MEC or the high-risk 
combination of AC provided protection against CINV in the 
overall phase, which was noninferior to palonosetron plus 
the conventional 3-day dexamethasone.46,47 On the basis of 
these evidences, the single-dose fosaprepitant regimen can 
contribute not only to enhance clinical implementation of 
guidelines but also to assess, when studied in combination 
with palonosetron, optimal schedules for use of dexametha-
sone in HEC setting. Moreover, results from trials evaluating 
the efficacy of single-dose fosaprepitant as a rescue therapy 
for breakthrough CINV are eagerly awaited.
The benefit of using a new, higher-cost agent as part of the 
CINV prophylaxis should be considered in the context of an 
increasing need to find ways to allocate limited resources in 
cancer care.48 Therefore, clinical practice guidelines should 
include cost-effectiveness information in order to enable guide-
line end-users to make decisions that account for real-world 
constraints while ensuring the highest quality care of CINV.49 
Direct costs of uncontrolled CINV rely on the need for rescue 
medication, unscheduled office visits, and emergency room 
admissions.35 In addition, reduced productivity at work or lost 
workdays for patients and/or caregivers may represent indirect 
costs resulting from uncontrolled CINV.36 Therefore, if the 
total savings achieved from lowering the rate of uncontrolled, 
delayed CINV outweigh the higher acquisition cost of a new 
drug, prophylaxis with this agent in clinical practice should 
be considered economically justified.50 Of interest, the use of 
aprepitant in CINV control was shown to be cost-effective 
in two European analyses,51,52 but a US study suggested that 
aprepitant provides only modest incremental benefit compared 
with conventional two-drug regimens against CINV caused by 
HEC.53 Nevertheless, the investigators also stated that routine 
use of aprepitant may be cost-effective in clinical settings 
where the likelihood of delayed CINV or the cost of rescue 
antiemetics is high. Economic analyses across countries, there-
fore, should evaluate the impact of newer antiemetic strategies 
including the single-dose fosaprepitant regimen on healthcare 
resource use secondary to poorly controlled CINV.
Conclusions
Provocative data from a randomized noninferiority trial 
demonstrate that a single dose of intravenous fosaprepitant 
150 mg on day 1 offers similar protection as the 3-day oral 
regimen of aprepitant in patients who are scheduled to receive 
cisplatin. The new dosage regimen of fosaprepitant can provide 
a simplified treatment option that maintains high protection 
while ensuring adherence to scheduled antiemetic  medication 
throughout most of the 5-day period encompassing the major 
risk for CINV. The single-dose regimen also retains the 
potential to make a meaningful contribution to CINV research 
devoted to the improvement of a patient’s quality of life.
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